Price movement over the last 24 hours
AFLAC Incorporated vs Koninklijke Philips NV — how do they compare? AFLAC Incorporated trades at $121.41 (market cap $61.84B), while Koninklijke Philips NV trades at $27.58 (market cap $27.30B). The key difference: AFLAC Incorporated is far larger — about 2.3× Koninklijke Philips NV's market cap, and Koninklijke Philips NV pays the higher dividend (3.59%). Which is the better fit depends on your goals.
| AFL | PHG | |
|---|---|---|
Market Cap | $61.84B | $27.30B |
Sector | Financials | Health |
52-Week High | $121.49 | $32.91 |
52-Week Low | $98.09 | $24.03 |
Enterprise Value | $70.50B | $33.57B |
Dividend Yield | 2.01% | 3.59% |
Signals from Pluang's Aura AI — not financial advice
Aflac (AFL) trades at $121.49, up 0.5% with a bullish technical signal supported by moving averages. The stock shows strong fundamentals with a 25.32% net income margin and 16.47% ROE, though recent Q1 2026 earnings missed expectations. Analyst consensus is mixed with 28% buy ratings and a $113.57 price target below current levels. Recent developments include strong dividend performance and upcoming Q2 2026 results announcement on August 6, 2026.
The outlook remains cautiously optimistic with solid profitability and dividend stability, but faces headwinds from recent earnings misses and premium valuation pressure. Key opportunities include continued growth in Japan and U.S. markets, while risks involve medical cost inflation and uneven revenue trends. The stock's current premium to analyst targets suggests limited near-term upside potential.
PHG trades at $28.23, up 1.77% with a bullish technical outlook supported by moving averages. The company shows improved profitability with net income turning positive at $895 million in 2025 after previous losses. Recent earnings beat expectations in two of the last three quarters, while analyst sentiment leans neutral with 40.9% buy ratings. Strong cash flow generation and strategic partnerships in healthcare technology position the company for continued recovery.
The stock presents a recovery story with improving fundamentals but faces execution risks in a competitive healthcare technology market. Valuation appears reasonable with P/E of 24.73 and P/S of 1.35, though debt levels remain elevated. Near-term catalysts include Q2 2026 earnings and continued AI integration in healthcare solutions, while macroeconomic pressures and competitive threats represent ongoing challenges.
Trailing returns across standard periods
Latest headlines on both assets
Aflac Inc offers supplemental health insurance and life insurance in the two largest insurance markets in the world, the U.S. and Japan. In addition to its cancer policies, the company has broadened its product offerings to include accidents, disability, and long-term-care insurance. It markets its products through independent distributors, selling most of its policies directly to consumers at their places of work.
Read more on AFL →Philips is a diversified global healthcare company operating in three segments: diagnosis and treatment, connected care, and personal health. About 50% of the company's revenue comes from the diagnosis and treatment segment, which features imaging systems, ultrasound equipment, image-guided therapy solutions and healthcare informatics. The connected care segment (27% of revenue) encompasses monitoring and analytics systems for hospitals and sleep and respiratory care devices, whereas the personal health business (remainder of revenue) includes electric toothbrushes and men's grooming and personal-care products. In 2021, Philips generated EUR 17.2 billion in sales and had 80,000 employees in over 100 countries.
Read more on PHG →